SCHEMBL4366909

SCHEMBL4366909

COC(=O)C(OC)C(C)(C)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
KCNN4 O15554 1/20 0.47
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
MDM4 O15151 1/20 0.41
MDM2 Q00987 1/20 0.41
MAPT P10636 1/20 0.40
POLB P06746 1/20 0.40
KIF11 P52732 1/20 0.40
CES1 P23141 1/20 0.40
EDNRB P24530 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373874 0.85 KCNN4 (0.46) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL7213724 0.81 KMT2A (0.50) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL25432602 0.80 KMT2A (0.48) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL4366561 0.80 KMT2A (0.48) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL1527235 0.79 KMT2A (0.47) KMT2AKCNN4HDAC3HDAC4HDAC1
Ammonia Solution, Strong SCHEMBL5356621 0.79 KMT2A (0.47) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL7208176 0.79 KMT2A (0.47) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL1527236 0.79 KMT2A (0.47) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL24115088 0.77 KMT2A (0.46) KMT2AKCNN4HDAC3HDAC4HDAC1
SCHEMBL15258811 0.77 KMT2A (0.46) KMT2AKCNN4HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626023-B2 Compounds for treating tumors WYETH (US) 2009-12-01 US disclosed
US-7626023-B2 Compounds for treating tumors WYETH (US) 2009-12-01 US disclosed
US-7626023-B2 Compounds for treating tumors WYETH (US) 2009-12-01 US disclosed
US-20080221181-A1 COMPOUNDS FOR TREATING TUMORS WYETH HOLDINGS CORPORATION (US) 2008-09-11 US disclosed
US-20080221181-A1 COMPOUNDS FOR TREATING TUMORS WYETH HOLDINGS CORPORATION (US) 2008-09-11 US disclosed
US-20080221181-A1 COMPOUNDS FOR TREATING TUMORS WYETH HOLDINGS CORPORATION (US) 2008-09-11 US disclosed
US-7390910-B2 Compounds for treating tumors WYETH (US) 2008-06-24 US disclosed
WO-2005016958-A2 COMPOUNDS FOR TREATING TUMORS WYETH HOLDINGS CORPORATION (US) 2005-02-24 WO disclosed
US-20050037977-A1 Compounds for treating tumors WYETH HOLDINGS CORPORATION (US) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221181-A1 COMPOUNDS FOR TREATING TUMORS RB1, MRPL9, BCOR KMT2A 1674/4885KCNN4 4506/4885HDAC3 1316/4885
US-20050037977-A1 Compounds for treating tumors RB1, MRPL9, BCOR KMT2A 1674/4885KCNN4 4506/4885HDAC3 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.